Neurogene CFO’s Planned Sale of 4,800 Shares Highlights Liquidity Move Amid Breakthrough Therapy Designation
Neurogene CFO Christine Mikail sells 4,800 shares under a pre‑approved plan; assess why insiders trade while the stock rises on FDA breakthrough news.
3 minutes to read